B lymphoproliferative diseases: Effective treatment, inhibited progression, and potential cures through
Srividya Swaminathan1, Ameae M Walker2
1Department of Systems Biology, Beckman Research Institute, City of Hope Comprehensive Cancer Center, Monrovia, CA, United States.
Abstract:
In this chapter, we describe a potential new approach to treat lymphoproliferative diseases through isoform-specific knockdown of the long form of the prolactin receptor. The chapter includes a summary of the clinical and experimental links between prolactin and such diseases and presents sufficient background about prolactin and its receptors to explain the rationale for our approach. This background also aims to explain why clinical correlations between circulating prolactin and lymphoproliferative diseases may not appear as great as perhaps they are. In the final sections, we summarize our experimental evidence supporting the use of a splice-modulating oligomer that specifically targets the long form of the prolactin receptor. The work used mouse models of systemic lupus erythematosus and diffuse large B-cell lymphoma, human databases, and normal and malignant human cells. We also refer to previous and current studies using the splice-modulating oligomer which demonstrate its lack of toxicity, including in normal immune cells. For each section, we provide a take-home message in bold font so that the reader has the option to focus briefly or delve into details supporting the take-home message.
Insights
This study explores a novel treatment for lymphoproliferative diseases by targeting the long form of the prolactin receptor. A splice-modulating oligomer shows promise in reducing disease while maintaining safety in immune cells.
Area of Science:
- Immunology
- Molecular Biology
- Oncology
Background:
- Prolactin and its receptors are implicated in lymphoproliferative diseases.
- Clinical correlations may be obscured by complex regulatory mechanisms.
- The long form of the prolactin receptor is a potential therapeutic target.
Purpose of the Study:
- To investigate a novel therapeutic strategy for lymphoproliferative diseases.
- To evaluate the efficacy and safety of targeting the long prolactin receptor.
- To elucidate the role of prolactin signaling in disease pathogenesis.
Main Methods:
- Utilized mouse models of systemic lupus erythematosus and diffuse large B-cell lymphoma.
- Analyzed human databases and both normal and malignant human cells.
- Employed a splice-modulating oligomer for isoform-specific knockdown of the prolactin receptor.
Main Results:
- Experimental evidence supports the use of a splice-modulating oligomer.
- The oligomer specifically targets the long form of the prolactin receptor.
- Demonstrated lack of toxicity in normal immune cells in previous and current studies.
Conclusions:
- Isoform-specific knockdown of the long prolactin receptor is a potential treatment for lymphoproliferative diseases.
- The splice-modulating oligomer is a safe and effective therapeutic candidate.
- Further research is warranted to translate these findings to clinical applications.
